NCT07785089Not yet recruiting
Ultrasound and Shear Wave Elastography Assessment of Entheses in Psoriatic Arthritis
Ultrasonography and Shear Wave Elastography Assessment of Enthesis Sites in Patients With Psoriatic Arthritis and Their Relationship With Disease Characteristics
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that frequently involves the entheses, where tendons, ligaments, and fascia insert into bone. Early detection of enthesitis is important for disease assessment and management. Conventional musculoskeletal ultrasonography, including grayscale and Power Doppler ultrasonography, can identify structural and inflammatory changes, while shear wave elastography (SWE) provides quantitative information about tissue stiffness. This observational cross-sectional study aims to evaluate bilateral enthesis sites using grayscale ultrasonography, Power Doppler ultrasonography, and SWE in patients with PsA and age- and sex-matched healthy controls. The study will investigate the relationship between imaging findings and clinical disease characteristics, disease activity, functional status, and laboratory parameters. The findings may improve understanding of enthesis involvement in PsA and clarify the potential role of multimodal ultrasound assessment, including SWE, in disease evaluation.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 26 Jul 2026
- Start date
- 27 Jul 2026
- Primary completion date
- 27 Jul 2027
- Lead sponsor
- Marmara University
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT07785089
What you commit to
- Study type: Observational
- Planned participants: 60
- From 27 Jul 2026 to the primary completion date, 27 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Psoriatic arthritis group:
- Age younger than 18 years.
- Refusal to participate in the study or inability/unwillingness to provide written informed consent.
- Inability to complete the clinical or ultrasonographic assessments.
- History of surgery, fracture, major trauma, or tendon rupture involving the enthesis sites to be evaluated.
- Local corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, or other local interventional treatment at the enthesis sites to be evaluated within the previous 3 months.
- Presence of acute traumatic tendinopathy, active soft tissue infection, open wound, or ulcer at the enthesis sites to be evaluated.
- Diagnosis of another inflammatory rheumatic disease or connective tissue disease other than psoriatic arthritis.
- Active infection, active malignancy, or severe systemic disease that may interfere with study assessments.
- Healthy control group:
- Age younger than 18 years.
- Refusal to participate in the study or inability/unwillingness to provide written informed consent.
- Inability to complete the clinical or ultrasonographic assessments.
- History or diagnosis of psoriasis, psoriatic arthritis, or any other inflammatory rheumatic disease.
- History of surgery, fracture, major trauma, or tendon rupture involving the enthesis sites to be evaluated.
- Local corticosteroid injection, platelet-rich plasma (PRP), prolotherapy, or other local interventional treatment at the enthesis sites to be evaluated within the previous 3 months.
- Presence of acute traumatic tendinopathy, active soft tissue infection, open wound, or ulcer at the enthesis sites to be evaluated.
- Active infection, active malignancy, or severe systemic disease that may interfere with study assessments.
Who the study is looking for
- Psoriatic arthritis group:
- Adults aged 18 years or older.
- Diagnosis of psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR).
- Ability to provide written informed consent.
- Willingness to undergo clinical assessment, laboratory evaluation, grayscale ultrasonography, Power Doppler ultrasonography, and shear wave elastography.
- Healthy control group:
- Adults aged 18 years or older.
- No history or diagnosis of inflammatory rheumatic disease.
- Age- and sex-matched to the psoriatic arthritis group.
- Ability to provide written informed consent.
- Willingness to undergo grayscale ultrasonography, Power Doppler ultrasonography, and shear wave elastography.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.